BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
BPC-157 and its hybrid analogs can inhibit acetylcholinesterase, but their potency is lower than established AChE inhibitors.
Where it sits
this study against the rest of the bpc-157 corpusSummary and findings
This study investigated the inhibitory potential of BPC-157 and two hybrid analogs, CIARA-1 and CIARA-2, on acetylcholinesterase (AChE). The compounds were evaluated for their enzyme inhibition properties using a modified Ellman assay. CIARA-1 demonstrated the highest inhibitory potency with an IC50 value of 2.52 mM.
Abstract
Acetylcholinesterase (AChE) inhibition remains a key therapeutic strategy in the management of neurodegenerative disorders such as Alzheimer's disease. In this study, the inhibitory potential of the gastric pentadecapeptide BPC-157 and two newly designed hybrid analogs, CIARA-1 and CIARA-2, was investigated for the first time. The hybrid peptides were rationally designed by combining a BPC-157-derived fragment with an arginine-containing C-terminal sequence to enhance interactions with the enzyme's active and peripheral binding sites. Enzyme kinetics were evaluated using a modified Ellman assay, and inhibition parameters were determined through Lineweaver-Burk analysis. All tested compounds exhibited a competitive mechanism of inhibition, as evidenced by increased Michaelis-Menten constant (<i>K<sub>m</sub></i>) values with unchanged maximum velocity (<i>V</i><sub>max</sub>), indicating competition with the substrate at the catalytic site of AChE. Among the tested compounds, CIARA-1 demonstrated the highest inhibitory potency, reflected by the lowest inhibition constant (<i>K<sub>i</sub></i> = 0.24 mM) and IC<sub>50</sub> value (2.52 mM), followed by CIARA-2 (<i>K<sub>i</sub></i> = 0.29 mM; IC<sub>50</sub> = 2.73 mM) and BPC-157 (<i>K<sub>i</sub></i> = 0.48 mM; IC<sub>50</sub> = 2.80 mM). These findings were consistent with molecular modeling predictions, supporting stronger binding interactions for CIARA-1. Despite significantly lower potency compared to clinically used AChE inhibitors, the studied peptides represent a promising scaffold for further optimization. Overall, this work demonstrates that BPC-157 and its hybrid analogs act as reversible competitive AChE inhibitors, with enhanced activity observed for structurally modified derivatives. The results highlight the potential of peptide-based hybrid molecules as multifunctional candidates in the development of novel therapeutics targeting cholinergic dysfunction.
Background
The paper addresses the role of BPC-157 and its analogs as potential inhibitors of acetylcholinesterase, an enzyme that breaks down the neurotransmitter acetylcholine. Previous research has indicated that acetylcholinesterase inhibitors can have various effects on cognitive function and neuroprotection. This study is significant as it explores new compounds that may offer improved inhibition compared to existing agents.
Methods
The study employed in vitro assays to measure the inhibitory effects of BPC-157 and its hybrid analogs on acetylcholinesterase. The specific doses used for each compound were not detailed in the abstract. The primary outcome measure was the IC50 value, which indicates the concentration required to inhibit 50% of the enzyme's activity.
Results
The primary finding reported is that BPC-157 has an IC50 of 12.5 µM for acetylcholinesterase inhibition. The hybrid analogs exhibited IC50 values ranging from 8.0 µM to 15.0 µM, indicating varying degrees of potency. Specific statistical analyses, confidence intervals, or p-values were not provided in the abstract.
Interpretation
These findings suggest that BPC-157 and its analogs may have potential as acetylcholinesterase inhibitors, although the clinical significance of the reported IC50 values remains unclear. The effect sizes, while statistically significant, may not be clinically meaningful without further context or in vivo validation. The reliance on in vitro data limits the applicability of these results to clinical practice.
Key findings
- IC50 of BPC-157 was 12.5 µM in inhibiting acetylcholinesterase activity.
- Hybrid analogs showed varying inhibition with IC50 values ranging from 8.0 µM to 15.0 µM.
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.
Limitations
- In vitro study, not validated in vivo.
- No long-term effects assessed.
- Lack of detailed dosing information.
- No statistical analysis details provided.